SQ OncoKey Core on Automated Workflow
The Sentosa SQ OncoKey Core is a family of panels consisting of four panels: A non-small cell lung cancer (NSCLC) panel, a colorectal cancer (CRC) panel, thyroid panel and a melanoma panel. All panels are Next-Generation Sequencing (NGS) tests. All tests are automated on the Sentosa workflow.
The Sentosa SQ OncoKey Core is intended to be used on the Sentosa SX101, the Sentosa SX FFPE II gDNA Kit, Sentosa ST401 and Sentosa SQ301 instruments. On this automated workflow 7 samples can be automatically processed and analysed within 2.5 days.
The Sentosa SQ OncoKey Core is for research use only (RUO), and not for use in diagnostic procedures.
SQ OncoKey Core Primer Set on Manual Workflow
The same OncoKey Core design for the NSCLC/CRC/Thyroid panel is also available as Sentosa SQ OncoKey Core Primer Set (96) which gives users a manual solution.
The Sentosa SQ OncoKey Core Primer Set contains the Core Primer pool, the OncoKey System Control and barcoded DNA adapters sufficient for up to 16 libraries per run and 96 in total. The Sentosa SQ OncoKey Core Primer Set is for research use only (RUO), and not for use in diagnostic procedures.
Sentosa SQ OncoKey Core Primer Set is designed to be used with the Ion AmpliSeq™ DNA Library Preparation kits for multiplex targeted libraries from DNA for sequencing on Sentosa SQ301 or the Ion PGM/S5/S5 XL systems, following the manufacturer's instructions for the details of the procedure.
Target Genes |
NSCLC | |
Number of Target Mutations |
Amplicon Locations in Exon(s) |
|
NRAS | 19 | 2, 3, 4 |
CTNNB1 | 5 | 3 |
PIK3CA | 14 | 11, 22 |
FGFR3 | 9 | 7, 9, 14 |
KIT | 8 | 11, 13, 17 |
EGFR | 10 | 18, 19, 20, 21 |
BRAF | 15 | 11, 15 |
RET | 1 | 16 |
PTEN | 3 | 5, 7 |
KRAS | 22 | 2, 3, 4 |
TP53 | 7 | 4, 6, 7 |
Total | 113 |
Target Genes |
CRC | |
Number of Target Mutations |
Amplicon Locations in Exon(s) |
|
NRAS | 19 | 2, 3, 4 |
CTNNB1 | 5 | 3 |
PIK3CA | 14 | 11, 22 |
FGFR3 | 9 | 7, 9, 14 |
KIT | 8 | 11, 13, 17 |
EGFR | 9 | 18, 19, 20, 21 |
BRAF | 15 | 11, 15 |
RET | 1 | 16 |
PTEN | 3 | 5, 7 |
KRAS | 22 | 2, 3, 4 |
TP53 | 7 | 4, 6, 7 |
Total | 112 |
Target Genes |
Thyroid | |
Number of Target Mutations |
Amplicon Locations in Exon(s) |
|
NRAS | 19 | 2, 3, 4 |
CTNNB1 | 5 | 3 |
PIK3CA | 14 | 11, 22 |
FGFR3 | 9 | 7, 9, 14 |
cKIT | - | - |
EGFR | 10 | 18, 19, 20, 21 |
BRAF | 15 | 11, 15 |
RET | 1 | 16 |
PTEN | 3 | 5, 7 |
KRAS | 22 | 2, 3, 4 |
TP53 | 7 | 4, 6, 7 |
Total | 105 |
*Not available with/applicable for the Oncokey Core Primer Set (RUO)
Sentosa Oncology Panels Flyer | RUO | EN |
Attribute | NSCLC | CRC | Thyroid |
Regulatory Status | RUO | ||
No. of Genes | 11 | 11 | 10 |
No. of Amplicons | 28 | 28 | 25 |
Target Mutations | 113 | 112 | 105 |
Sample Input | 10 µm section of FFPE sample with > 10% tumor content | ||
Sample Throughput | 7 samples and 1 system control sample | ||
Median Coverage | ≥ 1.000X | ||
Mutation Detection Sensitivity | 5% - 10% | ||
Hands on Time | ≤ 3 hours | ||
Turn around Time | 2.5 days including overnight sample incubation | ||
Pack Size | 4x8 |
Product | Pack Size | Item Number |
---|---|---|
Sentosa SQ 318 Chip Kit (8) RUO | 8 runs | 300301 |
Sentosa SQ CRC Panel Reagents (4x8) RUO | 4x8 | 300262 |
Sentosa SQ Melanoma Reagents (4x8) RUO | 4x8 | 300221 |
Sentosa SQ NSCLC Panel Reagents (4x8) RUO | 4x8 | 300357 |
Sentosa SQ Oncology Solutions (4x8) RUO | 4x8 | 300224 |
Sentosa SQ Sequencing Reagents (8) RUO | 8 | 300310 |
Sentosa SQ Sequencing Solutions (8) RUO | 8 | 300314 |
Sentosa SQ Sequencing Supplies (8) RUO | 8 | 300304 |
Sentosa SQ Thyroid Cancer Reagents (4x8) RUO | 4x8 | 300382 |
Sentosa ST Template Beads (8) RUO | 8 | 300320 |
Sentosa ST Template Reagents (8) RUO | 8 | 300317 |
Sentosa ST Template Solutions (8) RUO | 8 | 300323 |
Sentosa ST Template Supplies (8) RUO | 8 | 300326 |
Sentosa SX FFPE II gDNA Kit (4x8) RUO | 4x8 | 300231 |
For availability in your country, please contact your Vela Diagnostics sales representative. Availability is subject to country's regulatory approval.
For more product related documents, please contact us.